Omnipod Discover launch puts Insulet's data platform in focus
Insulet (PODD) has rolled out Omnipod Discover nationwide in the US, extending a web-based data platform that earlier limited-release users and healthcare professionals had already begun to adopt.
Recent trading hints at a short burst of optimism around Insulet, with a 7 day share price return of 4.97% and a 30 day gain of 9.46% to US$149.01. However, the 90 day share price return has fallen 11.02% and the 1 year total shareholder return is down 54.26%, pointing to longer term momentum that has faded even as product launches like Omnipod Discover refocus attention on the business.
Compare Insulet's digital health push with other medtech players building data driven tools by reviewing the hand picked 34 healthcare AI stocks that are already leaning into similar trends.
Insulet now has a widely used product line and a fresh data platform story, yet the share price is still well below last year's level. Is that a quality franchise on sale, or fairly marked down?
Most Popular Narrative: 11% Undervalued
On Simply Wall St's most followed view, Insulet's fair value of $167.17 sits above the recent $149.01 close, putting Omnipod Discover's rollout in the context of perceived undervaluation and execution questions.
Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, supported by Q2 2026 total revenue of US$802 million and 23% growth in the global customer base, points to Insulet gaining share in a growing diabetes device market, which can support ongoing revenue growth and operating leverage.
See why 23 investors see Insulet as 11% undervalued .
Result: Fair Value of $167.17 (UNDERVALUED)
Still, the Insulet story could shift quickly if type 2 churn remains more than double type 1, or if recall related issues weigh on new starts and costs.
Find out about the key risks to this Insulet narrative .
Another View: Insulet through a P/E lens
The first narrative leans on fair value estimates and long term forecasts. A simpler lens tells a tighter story. Insulet trades on a P/E of 27.5x, which is slightly above the US Medical Equipment industry at 27x, yet below peer averages at 37.9x and under its own fair ratio of 30x.
That mix of numbers suggests the stock is not obviously cheap or stretched on earnings, and the gap to the 30x fair ratio could either close through price moves or through results catching up. Which way do you think the adjustment happens first?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed views like these only get you so far. Pull up the numbers, pressure test Insulet's rewards and risks, and weigh the 3 key rewards
Looking for more investment ideas beyond Insulet?
Do not stop your research with Insulet when a whole universe of potential opportunities is sitting one screener away.
-
Target businesses the market may be overlooking by scanning the 21 high quality undiscovered gems , which pair strong fundamentals with less crowded coverage.
-
Focus on resilience first by reviewing the 30 resilient stocks with low risk scores , which score well on financial strength and risk metrics.
-
Hunt for quality at a marked down price by checking the 29 high quality undervalued stocks , which combine solid cash flows with supportive balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PODD .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
